Head-to-head · WeighScore
LillyDirect Foundayo vs Luma Meds
The verdict
LillyDirect Foundayo takes it — 67.2/100 to 57.8/100.
LillyDirect Foundayo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | LillyDirect Foundayo | Luma Meds |
|---|---|---|
| WeighScore | 67.2/100 | 57.8/100 |
| Grade | C | C |
| Scorecard rank | #173 | #391 |
| Semaglutide | Not disclosed | $249/mo (compounded) |
| Tirzepatide | Not disclosed | $299/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #173 · C
Strengths
- Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- Direct from manufacturer — no compounding, no third-party reseller
- Daily oral pill, no injections, no refrigeration
- Available in all 50 states
Where it loses points
- Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- $25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- Strict empty-stomach 30-minute window may be hard for some patients to follow
Graded #391 · C
Strengths
- LegitScript certified — a credibility mark fewer compounded GLP-1 providers carry
- Free discreet shipping and unlimited 24/7 support on every plan
- Compounded semaglutide and tirzepatide from FDA-regulated 503A/503B pharmacies
- '100,000+ members treated' claim with physician-supervised online care
- 3-month bundle pricing brings semaglutide as low as $140/mo
Where it loses points
- Compounding pharmacy partner not publicly named
- States available not published
- Monthly semaglutide ($249/mo) is above many lower-cost compounded competitors
- No oral formulation options listed
- Compounded medications are not FDA-approved
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.